PharmaNetics' heparin assay trial completed:
This article was originally published in Clinica
Executive Summary
PharmaNetics Inc has completed a Phase I field trial of its rapid in vitro assay for monitoring the anticoagulant effects of enoxaparin, Aventis Pharmaceutical's low molecular weight heparin product marketed in the US as Lovenox and elsewhere as Clexane. According to PharmaNetics, the results of the trial show a sufficient correlation with standard laboratory methods to justify proceeding with trials needed for FDA submission. PharmaNetics has optimised the assay's test card formulation and is now validating its manufacturing process.